An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
New Drugs for Type 2 Diabetes: Second-Line Therapy — Science Report [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep. (CADTH Therapeutic Review, No. 4.1b.)
Top results in this bookTable of Contents
Diabetes Medications for Adults With Type 2 Diabetes: An Update [Internet].
Bolen S, Tseng E, Hutfless S, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Apr. (Comparative Effectiveness Reviews, No. 173.)
Endotext [Internet].
Feingold KR, Anawalt B, Blackman MR, et al., editors.
South Dartmouth (MA): MDText.com, Inc.; 2000-.
Alogliptin Plus Metformin (Kazano) for Type 2 Diabetes Mellitus [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.
Exploratory Brief on Glucose Monitoring Technologies [Internet].
Corabian P, Chojecki D.
Edmonton (AB): Institute of Health Economics; 2017 Jan.
Canagliflozin (Invokana) for Type 2 Diabetes Mellitus [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Sep.
Alogliptin (Nesina) for Type 2 Diabetes Mellitus [Internet].
Clinical Review Report: Insulin Degludec (Tresiba): (Novo Nordisk Canada Inc): Indication: For once-daily treatment of adults with diabetes mellitus to improve glycemic control [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Dec.
Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.
Prevention and Control of Noncommunicable Diseases: Guidelines for Primary Health Care in Low Resource Settings.
Geneva: World Health Organization; 2012.
Clinical Review Report: Lixisenatide (Adlyxine): (Sanofi-aventis Canada Inc.): Indication: As an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with metformin, a sulfonylurea (alone or with metformin), pioglitazone (alone or with metformin), a basal insulin (alone or with metformin), when the therapy listed above does not provide adequate glycemic control [Internet].
Clinical Review Report: Insulin degludec and liraglutide injection (Xultophy): (Novo Nordisk Canada Inc.): Indication: An adjunct to lifestyle modifications, for the once-daily treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 U daily) or liraglutide (less than or equal to 1.8 mg daily) do not provide adequate glycemic control [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Dec.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
Clinical Review Report: Insulin glargine and lixisenatide injection (Soliqua): (Sanofi-Aventis): Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) alone or in combination with metformin [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jan.
Clinical Review Report: Ertugliflozin (Steglatro): (Merck Canada Inc.): Indication: Type 2 Diabetes Mellitus [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Feb.
Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus.
Geneva: World Health Organization; 2018.
Saxagliptin (Onglyza): Indicated in Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control in Combination with Metformin and a Sulfonylurea when Dual Therapy with these Two Agents, with Diet and Exercise, does not Provide Adequate Glycemic Control [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Nov.
Type 2 diabetes in adults: management: Evidence reviews for SGLT-2 inhibitors and GLP-1 mimetics.
London: National Institute for Health and Care Excellence (NICE); 2018 Mar. (NICE Guideline, No. 28.)
Clinical Review Report: Dapagliflozin (Forxiga) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Apr.
Screening for Abnormal Glucose and Type 2 Diabetes Mellitus: A Systematic Review to Update the 2008 U.S. Preventive Services Task Force Recommendation [Internet].
Selph S, Dana T, Bougatsos C, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Apr. (Evidence Syntheses, No. 117.)
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on